Vanguard Capital Management
ZNTL icon

Vanguard Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Vanguard Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.8M Buy
2,835,669
+524,962
+23% +$2.1M ﹤0.01% 2641
2026
Q1 		$5.41M Buy
+2,310,707
New +$5.97M ﹤0.01% 3031

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vanguard Capital Management's ZNTL Position: Q2 2026 in Review

Vanguard Capital Management increased its Zentalis Pharmaceuticals (ZNTL) stake by 23% in Q2 2026, buying an estimated $2.1M and bringing the position to 2,835,669 shares worth $13.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2641.

Vanguard Capital Management first reported a position in ZNTL in Q1 2026 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Vanguard Capital Management held 2,835,669 shares of Zentalis Pharmaceuticals worth $13.8M as of Q2 2026.
  • Vanguard Capital Management bought 524,962 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $2.1M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2641 holding.
  • Vanguard Capital Management first reported a position in Zentalis Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.